Citi Appointed as Depositary Bank for Mereo BioPharma’s ADR Programme
Citi, acting through Citibank N.A., has been appointed by Mereo BioPharma Group plc (“Mereo”) as depositary bank for its American Depositary Receipt (“ADR”) programme following the merger between Mereo and OncoMed Pharmaceuticals, Inc., pursuant to which OncoMed will become a wholly-owned indirect subsidiary of Mereo. Mereo’s ADRs trade on the Nasdaq Global Market under the symbol “MREO.” Each ADR represents five ordinary shares of Mereo. “We are confident that we will be able to assist Mereo in expanding their investor outreach through the support of our leading investor relations advisory team and our global equity distribution network.”. For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr. The Company announced positive Phase 2 data in May 2018 and recently announced the outline of the pivotal Phase 3 study including the primary and key secondary endpoints following the successful end of Phase 2 Type B meeting with the FDA;.